Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm
NCT07391215
5G-PEARL: Paxalisib in Malignant Brain Tumours (5G-PEARL)
5G-PEARL: Paxalisib in Combination With Temozolomide in Patients With High Grade Malignant Brain Tumours Within the 5G Platform
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Interventions
Paxalisib Temozolomide capsule
Updated 1 time since 2026 Last updated: Jan 29, 2026 Started: Jan 19, 2026 Primary completion: Jan 19, 2029 Completion: Jun 30, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1/PHASE2 clinical study on Glioblastoma Multiforme (GBM) and Malignant Primary Gliomas, this trial is actively recruiting participants. The trial is conducted by Cambridge University Hospitals NHS Foundation Trust and has accumulated 1 data snapshot since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Cambridge University Hospitals NHS Foundation Trust
- Cancer Research UK
- Institute of Cancer Research, United Kingdom
- Kazia Therapeutics Limited
- Minderoo Foundation
- Royal Marsden NHS Foundation Trust
Data source: Institute of Cancer Research, United Kingdom
For direct contact, visit the study record on ClinicalTrials.gov .